Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
Mov Disord. 2014 Mar;29(3):311-9. doi: 10.1002/mds.25657. Epub 2013 Oct 21.
The Unified Huntington's Disease Rating Scale is used to characterize motor impairments and establish motor diagnosis. Little is known about the timing of diagnostic confidence level categories and the trajectory of motor impairments during the prodromal phase. Goals of this study were to estimate the timing of categories, model the prodromal trajectory of motor impairments, estimate the rate of motor impairment change by category, and provide required sample size estimates for a test of efficacy in clinical trials. In total, 1010 gene-expanded participants from the Neurobiological Predictors of Huntington's Disease (PREDICT-HD) trial were analyzed. Accelerated failure time models were used to predict the timing of categories. Linear mixed effects regression was used to model the longitudinal motor trajectories. Age and length of gene expansion were incorporated into all models. The timing of categories varied significantly by gene expansion, with faster progression associated with greater expansion. For the median expansion, the third diagnostic confidence level category was estimated to have a first occurrence 1.5 years before diagnosis, and the second and first categories were estimated to occur 6.75 years and 19.75 years before diagnosis, respectively. Motor impairments displayed a nonlinear prodromal course. The motor impairment rate of change increased as the diagnostic confidence level increased, with added acceleration for higher progression scores. Motor items can detect changes in motor impairments before diagnosis. Given a sufficiently high progression score, there is evidence that the diagnostic confidence level can be used for prodromal staging. Implications for Huntington's disease research and the planning of clinical trials of efficacy are discussed.
统一亨廷顿病评定量表用于描述运动障碍并建立运动诊断。对于诊断置信度类别出现的时间以及前驱期运动障碍的轨迹知之甚少。本研究的目的是估计类别出现的时间,建立运动障碍的前驱轨迹模型,估计每个类别运动障碍变化的速度,并为临床试验的疗效测试提供所需的样本量估计。共有来自神经生物学预测亨廷顿病(PREDICT-HD)试验的 1010 名基因扩增参与者进行了分析。加速失效时间模型用于预测类别出现的时间。线性混合效应回归用于建立纵向运动轨迹模型。所有模型均纳入年龄和基因扩展长度。类别出现的时间因基因扩展而有显著差异,进展越快,扩展越大。对于中位数扩展,第三个诊断置信水平类别估计在诊断前 1.5 年首次出现,第二个和第一个类别分别估计在诊断前 6.75 年和 19.75 年出现。运动障碍表现出非线性前驱期过程。随着诊断置信度的增加,运动障碍的变化率增加,进展评分越高,加速越明显。运动项目可以在诊断前检测到运动障碍的变化。给定足够高的进展评分,有证据表明诊断置信度可用于前驱期分期。讨论了对亨廷顿病研究和疗效临床试验规划的影响。